IP Library Granted Patent US 11,602,511
Granted Patent B2
US 11,602,511 · App. 16/918,606 · Granted Mar 14, 2023

Amino acid compositions and methods for the treatment of liver diseases

Inventors: Michael Hamill (Wellesley, MA); Raffi Afeyan (Cambridge, MA); Chung-Wei Lee (Waban, MA); Harry Luithardt (Cambridge, MA)
Assignee: AXCELLA HEALTH INC.
A61K31/198A23L33/175A23L33/18A61K9/14A61K38/05A61K38/06A61P1/16A23V2250/0634
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,602,511
App. No.
16/918,606
Granted
Mar 14, 2023
Kind
B2
Abstract

This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

Claims (64)

1. A dietary composition comprising:

(a) L-leucine or a salt thereof, or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine;

(b) an arginine amino acid entity chosen from:

(i) L-arginine or a salt thereof,

(ii) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-arginine,

(iii) ornithine or a salt thereof,

(iv) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising ornithine,

(v) creatine or a salt thereof, or

(vi) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising creatine;

(c) L-glutamine or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine; and

(d) N-acetylcysteine (NAC) or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising NAC;

wherein when the dietary composition is in powder form, at least 50 wt. % of the total wt. of the dietary composition is one or more amino acid entities in free form,

wherein the total wt. % of (a)-(d) is greater than the total wt. % of other amino acid entities in the dietary composition,

wherein the dietary composition is chosen from a nutritional supplement, dietary formulation, functional food, medical food, or beverage.

2. The dietary composition of claim 1 , wherein methionine, tryptophan, and cysteine are present at less than 2 wt. % of the dietary composition when the dietary composition is in powder form.

3. The dietary composition of claim 1 , wherein methionine, tryptophan, or cysteine are absent in the dietary composition.

4. The dietary composition of claim 1 , wherein:

(1) the wt. % of the L-glutamine or a salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine in the dietary composition is greater than the wt. % of the arginine amino acid entity;

(2) the wt. % of the L-glutamine or a salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine in the dietary composition is equal to or greater than the wt. % of the L-leucine or a salt thereof, or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine; or

(3) the wt. % of the arginine amino acid entity in the dietary composition is greater than the wt. % of the L-leucine or a salt thereof, or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine.

5. The dietary composition of claim 1 , wherein:

the wt. % of the arginine amino acid entity in (b), the L-glutamine or a salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine in (c), and the NAC or a salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising NAC in (d) in combination is at least 50% of the dietary composition, when the dietary composition is in powder form, but not more than 90% of the dietary composition, when the dietary composition is in powder form.

6. The dietary composition of claim 1 , wherein:

(1) the ratio of the L-leucine or a salt thereof, or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine to the arginine amino acid entity is at least 1:4, and not more than 3:4;

(2) the ratio of the L-leucine or a salt thereof, or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine to the L-glutamine or a salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine is at least 1:4, and not more than 3:4; or

(3) the ratio of the arginine amino acid entity to the L-glutamine or a salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine is at least 1:4, and not more than 6:7.

7. The dietary composition of claim 1 , wherein the wt. ratio of: (a) L-leucine or a salt thereof, or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine, (b) the arginine amino acid entity, (c) the L-glutamine or a salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine, and (d) the NAC or salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising NAC is:

1+/−15%: 1.5+/−15%: 2+/−15%: 0.15+/−15%;

1+/−15%: 1.5+/−15%: 2+/−15%: 0.3+/−15%;

1+/−15%: 1.81+/−15%: 2+/−15%: 0.15+/−15%; or

1+/−15%: 0.75+/−15%: 1+/−15%: 0.225+/−15%.

8. The dietary composition of claim 1 , further comprising one or both of:

(1) L-isoleucine or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-isoleucine; or

(2) L-valine or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-valine.

9. The dietary composition of claim 8 , wherein the dietary composition comprises:

(a) L-leucine or a salt thereof;

(b) L-arginine or a salt thereof;

(c) L-glutamine or a salt thereof;

(d) NAC or a salt thereof;

(e) L-isoleucine or a salt thereof; and

(f) L-valine or a salt thereof.

10. The dietary composition of claim 9 , wherein the dietary composition comprises:

(a) L-leucine or a salt thereof;

(b) L-arginine or a salt thereof;

(c) L-glutamine or a salt thereof;

(d) NAC or a salt thereof;

(e) L-isoleucine or a salt thereof; and

(f) L-valine or a salt thereof;

wherein the wt. ratio of the L-leucine or a salt thereof, the L-isoleucine or a salt thereof, the L-valine or a salt thereof, the L-arginine or a salt thereof, the L-glutamine or a salt thereof, and the NAC or salt thereof is:

1+/−15%: 0.5+/−15%: 0.5+/−15%: 1.5+/−15%: 2+/−15%: 0.15+/−15%;

1+/−15%: 0.5+/−15%: 0.5+/−15%: 1.81+/−15%: 2+/−15%: 0.15+/−15%; or

1+/−15%: 0.5+/−15%: 0.5+/−15%: 1.5+/−15%: 2+/−15%: 0.3+/−15%.

11. The dietary composition of claim 1 , wherein at least one of (a)-(d) is a free amino acid.

12. The dietary composition of claim 1 , wherein at least one of (a)-(d) is in a salt form.

13. The dietary composition of claim 1 , wherein the dietary composition comprises a combination of not more than 15 different amino acid entities.

14. The dietary composition of claim 1 , further comprising a serine amino acid entity chosen from L-serine, L-glycine, or a combination thereof.

15. The dietary composition of claim 1 , wherein:

the arginine amino acid entity is chosen from:

i) L-arginine or a salt thereof,

ii) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-arginine,

iii) ornithine or a salt thereof, or

iv) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising ornithine.

16. The dietary composition of claim 1 , wherein the wt. % of the NAC or a salt thereof or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising NAC is at least 1%, but not more than 10% of the dietary composition, when the dietary composition is in powder form.

17. The dietary composition of claim 1 , further comprising L-serine or a salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2023
From: AXCELLA HEALTH INC.
To: AXCELLA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 066043/0001 →
RELEASE OF SECURITY INTEREST Recorded Dec 15, 2022
From: SLR INVESTMENT CORP.
To: AXCELLA HEALTH INC.
Reel/Frame 062137/0569 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 2, 2021
From: AXCELLA HEALTH INC.
To: SLR INVESTMENT CORP., AS AGENT
Reel/Frame 057435/0136 →
Continuity (7)
Continuation 15847289 · Dec 19, 2017
Provisional Application 62576267 · Oct 24, 2017
Provisional Application 62545322 · Aug 14, 2017
Provisional Application 62491773 · Apr 28, 2017
Provisional Application 62443205 · Jan 6, 2017
Provisional Application 62436073 · Dec 19, 2016
Related Publication 20200330417A1 · Oct 22, 2020